Amgen: Phase 3 Study of Kyprolis, Darzalex Meets Primary Endpoint

By Colin Kellaher

Amgen Inc. (AMGN) on Friday said a phase 3 study evaluating its cancer drug Kyprolis in combination with dexamethasone and Johnson & Johnson's (JNJ) Darzalex compared with Kyprolis and dexamethasone alone met its primary endpoint of progression-free survival.

The Thousand Oaks, Calif., biotechnology company said the regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.

Amgen said the phase 3 study confirms the benefit for patients shown in an earlier phase 1 study using the same combination, adding that it plans to discuss the data with health authorities in preparation for regulatory submissions.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 13, 2019 09:36 ET (13:36 GMT)

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024